← All trials
NCT04632537
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 7, 2020
- Primary completion
- Nov 30, 2022
- Completion date
- Apr 30, 2023
- First posted
- Nov 17, 2020
- Last posted
- Dec 9, 2020
- Enrollment
- 550
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Henry M. Jackson Foundation for the Advancement of Military MedicineLead sponsor
- Department of DefenseCollaborator
- Uniformed Services University of the Health SciencesOverall official - principal investigator
- Uniformed Services University of the Health SciencesStudy chair
- Uniformed Services University of the Health SciencesCollaborator
- Harvard UniversityCollaborator
- Harvard UniversityCollaborator
- Department of DefenseCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.